BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Zhang Y, Xu B, Shi J, Li J, Lu X, Xu L, Yang H, Hamad N, Wang C, Napier D, He S, Liu C, Liu Z, Qian H, Chen L, Wei X, Zheng X, Huang JA, Thibault O, Craven R, Wei D, Pan Y, Zhou BP, Wu Y, Yang XH.
Zhang Y, et al. Among authors: wei d, wei x.
Cell Oncol (Dordr). 2020 Dec;43(6):1049-1066. doi: 10.1007/s13402-020-00537-1. Epub 2020 Oct 2.
Cell Oncol (Dordr). 2020.
PMID: 33006750
Free PMC article.